Visit the Investors and Media section of Mirum's corporate website for webcast links and additional information. LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases ...
Mirum Pharmaceuticals, Inc. today announced its participation in the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) annual meeting taking place November ...